scholarly journals A case of desensitization of sorafenib after tumor lysis syndrome and erythema multiform in the patient with advanced hepatocellular carcinoma

Kanzo ◽  
2014 ◽  
Vol 55 (4) ◽  
pp. 221-227 ◽  
Author(s):  
Hisashi Nishida ◽  
Etsuro Hatano ◽  
Koji Tomiyama ◽  
Satoshi Seo ◽  
Koujiro Taura ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Tumor Lysis Syndrome ◽  
Advanced Hepatocellular Carcinoma ◽  
Tumor Lysis

scholarly journals Tumor Lysis Syndrome after Combination Therapy of Nivolumab and Sorafenib in a Woman with Advanced Hepatocellular Carcinoma

2020 ◽  
Vol 14 (2) ◽  
pp. 367-372 ◽  
Author(s):  
Tsai-Hung Yen ◽  
Chung-Hsin Chang ◽  
Sz-Iuan  Shiu
Keyword(s):  
Hepatocellular Carcinoma ◽  
Combination Therapy ◽  
Tumor Lysis Syndrome ◽  
Tumor Burden ◽  
Therapeutic Interventions ◽  
Advanced Hepatocellular Carcinoma ◽  
Large Tumor ◽  
Tumor Lysis ◽  
Advanced Hcc ◽  
First Case

Tumor lysis syndrome (TLS) is a life-threatening emergency that usually develops in rapidly proliferating hematologic malignancies or advanced solid tumor following cytotoxic chemotherapy or therapeutic interventions. TLS is especially rare in patients with hepatocellular carcinoma (HCC). Therefore, we present a case of a female patient with newly diagnosed advanced HCC who developed TLS and hepatic failure after receiving combination therapy of nivolumab and sorafenib. To our knowledge, this is the first case of TLS in a patient with advanced HCC owing to combination therapy of nivolumab and sorafenib. We also reviewed the literature and summarized the characteristics of TLS in patients with advanced HCC receiving various therapeutic interventions. The overall mortality rate was 63% and regarding the management, transarterial chemoembolization (TACE) was the most common etiology. TACE-related TLS developed more rapidly than sorafenib-related TLS. Furthermore, the efficacy and safety of combination therapy of nivolumab and sorafenib should be further evaluated, and TLS should still be a concern, especially in patients with large tumor burden.

Acute Tumor Lysis Syndrome After Thalidomide Therapy in Advanced Hepatocellular Carcinoma

2006 ◽  
Vol 11 (1) ◽  
pp. 87-88 ◽  
Author(s):  
Chien‐Chang Lee ◽  
Yuan‐Huei Wu ◽  
Shen‐Hung Chung ◽  
Wen‐Jone Chen
Keyword(s):  
Hepatocellular Carcinoma ◽  
Tumor Lysis Syndrome ◽  
Advanced Hepatocellular Carcinoma ◽  
Tumor Lysis

scholarly journals A Patient with Advanced Hepatocellular Carcinoma Treated with Sorafenib Tosylate Showed Massive Tumor Lysis with Avoidance of Tumor Lysis syndrome

2010 ◽  
Vol 49 (11) ◽  
pp. 991-994 ◽  
Author(s):  
Satoru Joshita ◽  
Kaname Yoshizawa ◽  
Kenji Sano ◽  
Satoshi Kobayashi ◽  
Tomohiro Sekiguchi ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Tumor Lysis Syndrome ◽  
Advanced Hepatocellular Carcinoma ◽  
Tumor Lysis

Fever after anti-programmed cell death-1 treatment to predict the response in advanced hepatocellular carcinoma.

2018 ◽  
Vol 36 (5_suppl) ◽  
pp. 90-90 ◽  
Author(s):  
San-Chi Chen
Keyword(s):  
Cell Death ◽  
Programmed Cell Death ◽  
Partial Response ◽  
Tumor Lysis Syndrome ◽  
Laboratory Data ◽  
Complete Response ◽  
Advanced Hepatocellular Carcinoma ◽  
Sorafenib Treatment ◽  
Tumor Lysis

90 Background: Anti-programmed cell death (PD)-1, an immune checkpoint inhibitor, has been recently approved for the treatment of patients with HCC following prior sorafenib. However, a reliable predictor of treatment response has not been established. Patients who experienced immune-related adverse events (irAEs) of any grade yielded a significantly higher response rate than did those did not experience irAEs. Methods: Three cases of advanced HCC with or without previous sorafenib treatment, underwent anti-PD-1 treatment (pembrolizumab, 2 mg/kg, at 3-week interval) with or without combination of sorafenib (400mg daily). Results: Case 1 Fever (38.3°C) developed 2 days after anti-PD-1 treatment. The fever persisted for 2 months and gradually subsided (Figure 2B). Follow-up computed tomography (CT) revealed persistent tumor shrinkage and complete response at the latest time of examination (Figure 1B); the treatment is ongoing. Case 2 Spiking fever developed after each time of anti-PD-1 treatment. Follow-up CT revealed a remarkable decrease in the tumor size (3 cm), resulting in a partial response (Figure 1D); the treatment is ongoing. Case 3 Twelve days after the treatment, the patient complained of fever and general weakness. Laboratory data revealed tumor lysis syndrome and disseminated intravascular coagulopathy (DIC). HBV, hepatitis B virus; HCV, hepatitis C virus; BCLC, Barcelona Clinic Liver Cancer; AFP, alpha-fetoprotein; TACE, transarterial chemoembolization; CR, complete response; PR, partial response. Conclusions: Fever may be an early predictor of response to anti-PD-1 treatment. The degree of fever seemed to be correlated with tumor burden. High fever may suggest cytokine storm and possible tumor lysis syndrome. Early detection is necessary for the immediate prescription of steroids and management of tumor lysis.[Table: see text]

Sign in / Sign up

Export Citation Format

Share Document